Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Más filtros













Base de datos
Intervalo de año de publicación
1.
Biomed Pharmacother ; 140: 111744, 2021 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-34049223

RESUMEN

Endometrial cancer (EC) is the most common neoplasm of the female reproductive tract in the developed world. Patients usually are diagnosed in early stage having a good prognosis. However, up to 20-25% of patients are diagnosed in advanced stages and have a higher risk of recurrence, making the prognosis worse. Previously studies identified ANXA2 as a predictor of recurrent disease in EC even in low risk patients. Furthermore, Circulating Tumor Cells (CTC) released from the primary tumor into the bloodstream, are plasticity entities responsible of the process of metastasis, becoming into an attractive clinical target. In this work we validated ANXA2 expression in CTC from high-risk EC patients. After that, we modelled in vitro and in vivo the tumor cell attachment of ANXA2-expressing CTC to the endothelium and the homing for the generation of micrometastasis. ANXA2 overexpression does not provide an advantage in the adhesion process of CTC, but it could be playing an important role in more advanced steps, conferring a greater homing capacity. We also performed a high-throughput screening (HTS) for compounds specifically targeting ANXA2, and selected Daunorubicin as candidate hit. Finally, we validated Daunorubicin in a 3D transendothelial migration system and also in a in vivo model of advanced EC, demonstrating the ability of Daunorubicin to inhibit the proliferation of ANXA2-overexpressing tumor cells.


Asunto(s)
Anexina A2/metabolismo , Neoplasias Endometriales/metabolismo , Neoplasias Endometriales/patología , Animales , Anexina A2/genética , Adhesión Celular , Línea Celular , Movimiento Celular/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Daunorrubicina/farmacología , Daunorrubicina/uso terapéutico , Neoplasias Endometriales/tratamiento farmacológico , Neoplasias Endometriales/genética , Endotelio/fisiología , Femenino , Ensayos Analíticos de Alto Rendimiento , Humanos , Biopsia Líquida , Ratones , Modelos Biológicos , Células Neoplásicas Circulantes
2.
Sci Rep ; 9(1): 7556, 2019 05 17.
Artículo en Inglés | MEDLINE | ID: mdl-31101830

RESUMEN

CD26 displays variable levels between effector (TH17 ≫ TH1 > TH2 > Treg) and naïve/memory (memory > naïve) CD4+ T lymphocytes. Besides, IL-6/IL-6R is associated with TH17-differentiation and asthma severity. Allergic/atopic asthma (AA) is dominated by TH2 responses, while TH17 immunity might either modulate the TH2-dependent inflammation in AA or be an important mechanism boosting non-allergic asthma (NAA). Therefore, in this work we have compared the expression of CD26 and CD126 (IL-6Rα) in lymphocytes from different groups of donors: allergic (AA) and non-allergic (NAA) asthma, rhinitis, and healthy subjects. For this purpose, flow cytometry, haematological/biochemical, and in vitro proliferation assays were performed. Our results show a strong CD26-CD126 correlation and an over-representation of CD26- subsets with a highly-differentiated effector phenotype in AA (CD4+CD26-/low T cells) and NAA (CD4-CD26- γδ-T cells). In addition, we found that circulating levels of CD26 (sCD26) were reduced in both AA and NAA, while loss of CD126 expression on different leukocytes correlated with higher disease severity. Finally, selective inhibition of CD26-mRNA translation led to enhanced T cell proliferation in vitro. These findings support that CD26 down-modulation could play a role in facilitating the expansion of highly-differentiated effector T cell subsets in asthma.


Asunto(s)
Asma/inmunología , Dipeptidil Peptidasa 4/metabolismo , Receptores de Interleucina-6/metabolismo , Linfocitos T Reguladores/inmunología , Células TH1/inmunología , Células Th2/inmunología , Adolescente , Adulto , Anciano , Asma/patología , Estudios de Casos y Controles , Dipeptidil Peptidasa 4/sangre , Dipeptidil Peptidasa 4/genética , Femenino , Citometría de Flujo , Humanos , Activación de Linfocitos/inmunología , Masculino , Persona de Mediana Edad , Receptores de Interleucina-6/genética , Índice de Severidad de la Enfermedad , Adulto Joven
3.
EBioMedicine ; 39: 118-131, 2019 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-30555045

RESUMEN

BACKGROUND: Excitatory amino acid transporter 2 (EAAT2) plays a pivotal role in glutamate clearance in the adult brain, thereby preventing excitotoxic effects. Considering the high efficacy of EAAT2 for glutamate uptake, we hypothesized that the expression of this transporter in mesenchymal stem cells (MSCs) for systemic administration could yield a cell-based glutamate-grabbing therapy, combining the intrinsic properties of these cells with excitotoxic protection. METHODS: To address this hypothesis, EAAT2-encoding cDNA was introduced into MSCs and human embryonic kidney 293 cells (HEK cells) as the control cell line. EAAT2 expression and functionality were evaluated by in vitro assays. Blood glutamate-grabbing activity was tested in healthy and ischemic rat models treated with 3 × 106 and 9 × 106 cells/animal. FINDINGS: The expression of EAAT2 in both cell types conferred the expected glutamate-grabbing activity in in vitro and in vivo studies. The functional improvement observed in ischemic rats treated with EAAT2-HEK at low dose, confirmed that this effect was indeed mediated by the glutamate-grabbing activity associated with EAAT2 functionality. Unexpectedly, both cell doses of non-transfected MSCs induced higher protection than transfected EAAT2-MSCs by another mechanism independent of the glutamate-grabbing capacity. INTERPRETATION: Although the transfection procedure most likely interferes with some of the intrinsic protective mechanisms of mesenchymal cells, the results show that the induced expression of EAAT2 in cells represents a novel alternative to mitigate the excitotoxic effects of glutamate and paves the way to combine this strategy with current cell therapies for cerebral ischemia.


Asunto(s)
Isquemia Encefálica/terapia , Proteínas de Transporte de Glutamato en la Membrana Plasmática/genética , Ácido Glutámico/sangre , Células Madre Mesenquimatosas/metabolismo , Animales , Isquemia Encefálica/metabolismo , Línea Celular , Modelos Animales de Enfermedad , Transportador 2 de Aminoácidos Excitadores , Proteínas de Transporte de Glutamato en la Membrana Plasmática/metabolismo , Células HEK293 , Humanos , Masculino , Trasplante de Células Madre Mesenquimatosas , Células Madre Mesenquimatosas/citología , Ratas , Transfección
4.
Ann Neurol ; 84(2): 260-273, 2018 08.
Artículo en Inglés | MEDLINE | ID: mdl-30014516

RESUMEN

OBJECTIVE: Blood/brain-glutamate grabbing is an emerging concept in the treatment of acute ischemic stroke, where essentially the deleterious effects of glutamate after ischemia are ameliorated by coaxing glutamate to enter the bloodstream and thus reducing its concentration in the brain. Aiming to demonstrate the clinical efficacy of blood glutamate grabbers in patients with stroke, in this study, we resorted to a drug-repositioning strategy for the discovery of new glutamate-grabbing drugs. METHODS: The glutamate-grabbing ability of 1,120 compounds (90% of which were drugs approved by the US Food and Drug Administration) was evaluated during an in vitro high-throughput screening campaign. Subsequently, the protective efficacy of the selected drugs was probed in an ischemic animal model and finally tested in stroke patients. RESULTS: Riboflavin (vitamin B2 ) was identified as the main hit compound. In ischemic animal models treated with riboflavin (1mg/kg), it was confirmed that blood glutamate reduction was associated with a significant reduction of infarct size. These results led to a randomized, double-blind, phase IIb clinical trial with patients with stroke. Fifty patients were randomized to 1 of the 2 study arms: the control group (placebo) and the experimental group (20mg of riboflavin [vitamin B2 Streuli@ ). Decrease in glutamate concentration was significantly greater (p < 0.029) in the treated group. Comparative analysis of the percentage improvement on the National Institutes of Health Stroke Scale score at discharge was slightly higher in the riboflavin-treated group than in the placebo group (33.7 ± 43.7 vs 48.9 ± 42.4%, p = 0.050). INTERPRETATION: This translational study represents the first human demonstration of the efficacy of blood glutamate grabbers in the treatment of patients with stroke, paving the way for the development of a promising novel protective therapy. Ann Neurol 2018;84:260-273.


Asunto(s)
Barrera Hematoencefálica/metabolismo , Isquemia Encefálica/sangre , Ácido Glutámico/sangre , Accidente Cerebrovascular/sangre , Animales , Barrera Hematoencefálica/efectos de los fármacos , Isquemia Encefálica/diagnóstico , Isquemia Encefálica/tratamiento farmacológico , Método Doble Ciego , Femenino , Estudios de Seguimiento , Humanos , Masculino , Ratas , Ratas Sprague-Dawley , Reproducibilidad de los Resultados , Riboflavina/farmacología , Riboflavina/uso terapéutico , Accidente Cerebrovascular/diagnóstico , Accidente Cerebrovascular/tratamiento farmacológico , Complejo Vitamínico B/farmacología , Complejo Vitamínico B/uso terapéutico
5.
Cytometry A ; 81(10): 843-55, 2012 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-22949266

RESUMEN

A major obstacle hampering the therapeutic application of regulatory T (Treg) cells is the lack of suitable extracellular markers, which complicates their identification/isolation. Treg cells are normally isolated via CD25 (IL-2Rα) targeting, but this protein is also expressed by activated CD4(+) effector T (Teff) lymphocytes. Other extracellular (positive or negative) Treg selection markers (e.g., HLA-DR, CD127) are also nonspecific. CD26 is an extracellular peptidase whose high expression has been traditionally used as an indicator of immune activation and effector functions in T cells. Now, we provide flow cytometry data showing high levels of CD26 within CD4(+)CD25(-) or CD4(+)FoxP3(-/low) effector T (Teff) lymphocytes, but negative or low levels (CD26(-/low)) in Treg cells selected according to the CD4(+)CD25(high) or the CD4(+)FoxP3(high) phenotype. Unlike the negative marker CD127 (IL-7Rα), which is down modulated in CD4(+) Teff lymphocytes after TCR triggering, most of these cells upregulate CD26 and take a CD4(+)CD25(+/high) CD26(+) phenotype upon activation. In contrast, there is only a slight upregulation within Treg cells (CD4(+)CD25(high) CD26(-/low)). Thus, differences in CD26 levels between Treg and Teff subsets are stable, and assessment of this marker, in combination with others like CD25, FoxP3, or CD127, may be useful during the quantitative evaluation or the isolation of Treg cells in samples containing activated Teff lymphocytes (e.g., from patients with autoimmune/inflammatory diseases).


Asunto(s)
Dipeptidil Peptidasa 4/inmunología , Epítopos de Linfocito T/inmunología , Inmunofenotipificación/métodos , Linfocitos T Reguladores/metabolismo , Biomarcadores/metabolismo , Dipeptidil Peptidasa 4/genética , Epítopos de Linfocito T/genética , Citometría de Flujo , Factores de Transcripción Forkhead/genética , Factores de Transcripción Forkhead/inmunología , Regulación de la Expresión Génica/inmunología , Humanos , Subunidad alfa del Receptor de Interleucina-2/genética , Subunidad alfa del Receptor de Interleucina-2/inmunología , Subunidad alfa del Receptor de Interleucina-7/genética , Subunidad alfa del Receptor de Interleucina-7/inmunología , Linfocitos T Reguladores/citología , Linfocitos T Reguladores/inmunología
6.
Anal Chim Acta ; 658(1): 18-31, 2010 Jan 18.
Artículo en Inglés | MEDLINE | ID: mdl-20082770

RESUMEN

Serum is a typical sample for non-invasive studies in clinical research. Its proteome characterization is challenging, since requires extensive protein depletion. Methods used nowadays for removal of high-abundance proteins are expensive or show quite often a low loading capacity, which has strong repercussions on the number of samples and replicates per analysis. In order to deplete immunoglobulins (Igs) and albumin (HSA) from 1 mL serum samples, we have developed a protocol based on a combination of thiophilic chromatography, not previously used in clinical proteomics, and a HSA-specific resin. Ig/HSA-depleted samples, immunoglobulinome and albuminone were analyzed by 2-DE. Thiophilic chromatography, coupled with HSA-depletion, allows a good 2-DE resolution as well as the visualization of new spots. Moreover, it yields enough protein to evaluate technical variability and facilitate subsequent protein identification. To validate the protocol, we carried out a preliminary comparative study between triplicate Igs/HSA-depleted serum samples from healthy control individuals and recently diagnosed/untreated rheumatoid arthritis (RA) patients. RA patients showed several acute phase proteins, as well as additional serum proteins, differentially and significantly regulated. Therefore, thiophilic chromatography can be used as an efficient and economical method in 2-DE to deplete immunoglobulins from large human serum samples before a more extensive fractioning.


Asunto(s)
Proteínas Sanguíneas/química , Electroforesis en Gel Bidimensional/métodos , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción/métodos , Compuestos de Sulfhidrilo/química , Artritis Reumatoide/diagnóstico , Proteínas Sanguíneas/análisis , Cromatografía en Gel , Humanos , Inmunoglobulinas/aislamiento & purificación , Albúmina Sérica/aislamiento & purificación , Tripsina/metabolismo
7.
Immunobiology ; 214(3): 187-96, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-19215801

RESUMEN

According to some authors, membrane compartmentalization is a key regulator of CD45 function. Indeed, it has been described that CD45 repositioning from raft microdomains to phospholipid-rich plasma membrane areas leads to the activation of extracellular signal-regulated kinases (ERKs). We have previously shown that interleukin-12 (IL-12) increases the expression of CD26, promoting the interaction of CD26 with CD45R0 (a CD45 isoform) and removing CD45R0 from lipid rafts. Thus, this IL-12-dependent removal of CD45RO from rafts could, hypothetically, fulfill functions like the activation of the ERK1/2 pathway. IL-12 is an important interleukin for T cells. Upon interaction with its receptor (interleukin-12 receptor; IL-12R), this cytokine triggers a signalling cascade, where the classical Janus kinase (JAK)-signal transducers and activators of transcription (STAT) pathway and other additional routes participate. Due to the promitogenic effect of IL-12 and the influence of this cytokine on CD45RO compartmentalization, ERK kinases were likely candidates to be downstream of IL-12R. However, several research groups have rejected a role for these kinases. Now, results in this paper show that the IL-12R binding, similar to the stimulation via T cell receptor (TCR), promotes the activation of the Raf/MEK-1/ERK1/2 pathway. In addition, the IL-12R-associated Janus kinase JAK2, but not TYK2, seems upstream of this important pathway for the proliferation of human T cells. However, even though c-Myc is slightly up-regulated by IL-12 and partially mediates the proliferative effect of IL-12, this transcription factor was not found downstream of ERK1/2.


Asunto(s)
Interleucina-12/metabolismo , Janus Quinasa 2/metabolismo , Subunidades de Proteína/metabolismo , Receptores de Interleucina-12/metabolismo , Linfocitos T/metabolismo , Proliferación Celular , Células Cultivadas , Activación Enzimática/efectos de los fármacos , Humanos , Interferón gamma/metabolismo , Interleucina-12/inmunología , Janus Quinasa 2/inmunología , Antígenos Comunes de Leucocito , Activación de Linfocitos/efectos de los fármacos , Fitohemaglutininas/inmunología , Subunidades de Proteína/genética , Subunidades de Proteína/inmunología , Receptores de Interleucina-12/genética , Receptores de Interleucina-12/inmunología , Transducción de Señal/inmunología , Linfocitos T/citología , Linfocitos T/inmunología , Tirfostinos/farmacología
8.
J Membr Biol ; 227(1): 1-12, 2009 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-19067026

RESUMEN

IL-12 is a cytokine that stimulates the expression of CD26, a T cell- and raft-associated ectopeptidase. IL-12 also enhances the interaction between CD26 and CD45RO, which removes the phosphatase CD45RO from raft microdomains. Since Janus kinases are known CD45 substrates, our hypothesis was that this relocation of CD45RO in nonraft areas of the membrane could be important to switch off the signaling via cytokine receptors, e.g., the IL-12 receptor (IL-12R). Accordingly, both IL-12R and CD45RO should be equally positioned in the cell membrane upon IL-12R ligation. However, there were no data available on the membrane distribution of IL-12R on human T cells. Working with phytohemagglutinin (PHA) lymphoblasts, we tried to fill that gap. The high-affinity IL-12R is made of two chains: IL-12Rbeta1 and IL-12Rbeta2. Using flow cytometry, Western blot and confocal microscopy, we obtained data suggesting that IL-12Rbeta1 is mainly associated to phospholipid-rich membrane areas, a location even enhanced upon IL-12 incubation of PHA blasts. Instead, IL-12Rbeta2 is found more segregated into membrane rafts, which could explain why two IL-12-triggered events, T-cell proliferation and ERK1/2 activation, are both methyl-beta-cyclodextrin-sensitive events. Ligation of IL-12R with IL-12 seems to induce a partial enrichment of IL-12Rbeta2 in phospholipid-rich areas, where according to our data IL-12Rbeta1 is already present. Therefore, although new data will be required, the present results support the initial hypothesis.


Asunto(s)
Membrana Celular/metabolismo , Microdominios de Membrana , Receptores de Interleucina-12/metabolismo , Linfocitos T/metabolismo , Adyuvantes Inmunológicos/farmacología , Western Blotting , Proliferación Celular , Células Cultivadas , Detergentes/farmacología , Citometría de Flujo , Técnica del Anticuerpo Fluorescente , Humanos , Interleucina-12/farmacología , Leucocitos Mononucleares/citología , Leucocitos Mononucleares/metabolismo , Leucocitos Mononucleares/ultraestructura , Proteína Quinasa 1 Activada por Mitógenos/metabolismo , Proteína Quinasa 3 Activada por Mitógenos/metabolismo , Octoxinol/farmacología , Fosforilación/efectos de los fármacos , Fitohemaglutininas/farmacología , Transducción de Señal , Linfocitos T/citología , Linfocitos T/ultraestructura , beta-Ciclodextrinas/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA